CA SB1191

Adds pharmacogenomic testing as a covered Medi-Cal benefit under the "Utilizing Pharmacogenomics to Greatly Reduce Adverse Drug Events (UPGRADE) Act."

Covers testing when a medication is being considered or administered for a Medi-Cal beneficiary's condition and has a known gene-drug or drug-drug-gene interaction demonstrated to be clinically actionable by the FDA or Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines.

Requires testing to be ordered by an enrolled Medi-Cal clinician or pharmacist and limits reimbursement to a single Current Procedural Terminology (CPT) or Healthcare Common Procedure Coding System (HCPCS) code per test.

Allows sample collection at home, in a pharmacy, or at a health facility without impacting Medi-Cal reimbursement rates.

Becomes operative only upon legislative appropriation for implementation purposes.